GeneDx, a fast-growing biotech doing exome and genomic testing, has seen big returns on Wall Street as appetite for its tests grow in the clinic.

Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed's full product ...